Home > Search Results: Burcklen, Michel
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
Results overview: Found 1 records in 0.02 seconds.
Articles, 1 records found
Articles 1 records found  
1.
10 p, 391.9 KB Ponesimod Compared with Teriflunomide in Patients with Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study : A Randomized Clinical Trial / Kappos, Ludwig (University of Basel) ; Fox, Robert J. (Cleveland Clinic) ; Burcklen, Michel (Actelion Pharmaceuticals) ; Freedman, Mark S. (University of Ottawa) ; Kubala Havrdova, Eva (Charles University) ; Hennessy, Brian (Actelion Pharmaceuticals) ; Hohlfeld, Reinhard (Ludwig Maximilians University Munich) ; Lublin, Fred (Icahn School of Medicine at Mount Sinai) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Pozzilli, Carlo (Sapienza University of Rome) ; Scherz, Tatiana (Actelion Pharmaceuticals) ; D'Ambrosio, Daniele (Galapagos GmbH) ; Linscheid, Philippe (Actelion Pharmaceuticals) ; Vaclavkova, Andrea (Actelion Pharmaceuticals) ; Pirozek-Lawniczek, Magdalena (Actelion Pharmaceuticals) ; Kracker, Hilke (Actelion Pharmaceuticals) ; Sprenger, Till (University of Basel) ; Universitat Autònoma de Barcelona
Importance: To our knowledge, the Oral Ponesimod Versus Teriflunomide In Relapsing Multiple Sclerosis (OPTIMUM) trial is the first phase 3 study comparing 2 oral disease-modifying therapies for relapsing multiple sclerosis (RMS). [...]
2021 - 10.1001/jamaneurol.2021.0405
JAMA Neurology, Vol. 78 Núm. 5 (may 2021) , p. 558-567  
Detailed record - Creative Commons

See also: similar author names
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with